Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Moreno-Martet

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Expert Review of Clinical Pharmacology|November 25, 2011
Cannabinoids, multiple sclerosis and neuroprotectionEva de Lago, María Gómez-Ruiz, Miguel Moreno-Martet, et al.
CNS Neuroscience & Therapeutics|April 8, 2014
Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosisMiguel Moreno-Martet, Francisco Espejo-Porras, Javier Fernández-Ruiz, et al.
Neuropharmacology|February 21, 2012
Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effectsEva de Lago, Miguel Moreno-Martet, Ana Cabranes, et al.
Neuroscience Letters|December 31, 2011
Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseasesMiguel Moreno-Martet, Leyre Mestre, Frida Loría, et al.
Multiple Sclerosis and Related Disorders|November 23, 2015
The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptorsMiguel Moreno-Martet, Ana Feliú, Francisco Espejo-Porras, et al.
British Journal of Pharmacology|May 7, 2011
Prospects for cannabinoid therapies in basal ganglia disordersJavier Fernández-Ruiz, Miguel Moreno-Martet, Carmen Rodríguez-Cueto, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Expert Review of Clinical Pharmacology|November 25, 2011
Cannabinoids, multiple sclerosis and neuroprotectionEva de Lago, María Gómez-Ruiz, Miguel Moreno-Martet, et al.
CNS Neuroscience & Therapeutics|April 8, 2014
Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosisMiguel Moreno-Martet, Francisco Espejo-Porras, Javier Fernández-Ruiz, et al.
Neuropharmacology|February 21, 2012
Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effectsEva de Lago, Miguel Moreno-Martet, Ana Cabranes, et al.
Neuroscience Letters|December 31, 2011
Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseasesMiguel Moreno-Martet, Leyre Mestre, Frida Loría, et al.
Multiple Sclerosis and Related Disorders|November 23, 2015
The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptorsMiguel Moreno-Martet, Ana Feliú, Francisco Espejo-Porras, et al.
British Journal of Pharmacology|May 7, 2011
Prospects for cannabinoid therapies in basal ganglia disordersJavier Fernández-Ruiz, Miguel Moreno-Martet, Carmen Rodríguez-Cueto, et al.
Pageof 1